Avoid common mistakes on your manuscript.
1 Correction to: High Blood Pressure & Cardiovascular Prevention https://doi.org/10.1007/s40292-021-00503-4
In the online version of the article section 8 (Obesity), para 6, lines 1 to 5 which read as:
Medications approved in Europe for weight loss in obese subjects currently include the lipase inhibitor orlistat at the dosage of 120 mg, of the GLP1-RA semaglutide 3 mg administered weekly and the combination of naltrexone and bupropione.
should read:
Medications approved in Europe for weight loss in obese subjects currently include the lipase inhibitor orlistat at the dosage of 120 mg, the GLP1-RA liraglutide 3 mg administered daily or semaglutide 2.4 mg administered weekly and the combination of naltrexone and bupropione.
In online version of the article Section 8 (Obesity), table (New recommendation), third point which reads as:
Medications for weight loss in obese subjects, including orlistat, semaglutide and the combination of naltrexone and bupropione may be considered when energy restriction and exercise are not sufficient.
should read:
Medications for weight loss in obese subjects, including orlistat, liraglutide, semaglutide and the combination of naltrexone and bupropione may be considered when energy restriction and exercise are not sufficient.
The original article has been corrected.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Volpe, M., Gallo, G., Modena, M.G. et al. Correction to: Updated Recommendations on Cardiovascular Prevention in 2022: An Executive Document of the Italian Society of Cardiovascular Prevention. High Blood Press Cardiovasc Prev 29, 103 (2022). https://doi.org/10.1007/s40292-022-00508-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40292-022-00508-7